Gary J. Gershik

Thomson Reuters Stand-out Lawyer (2025)
IAM Strategy 300 Global Leaders 2025
IAM Strategy 300 (2024) and IAM 1000 (2024, 2025)
IP Stars
Super Lawyer 2024 – Intellectual Property, Intellectual Property Litigation
Super Lawyers Award 2023 – New York Metro
18th Most Active Attorney in Bio-Tech (out of 11,732), Patexia Prosecution Award, 2023

Hon. William C. Conner Inn of Court
New York State Bar Association
New York Intellectual Property Law Association (NYIPLA)
American Intellectual Property Law Association (AIPLA)
Association of the Bar of the City of New York

Registered to Practice Before the U.S. Patent and Trademark Office

U.S. Court of Appeals Federal Circuit;
U.S. Patent and Trademark Office;
U.S. District Court for the Southern District of New York;
U.S. District Court for the Eastern District of New York;
New York;

New York Law School, J.D., 1997;
Columbia University School of Engineering, B.S., Chemical Engineering, 1993

Representative Matters

• Australian Government’s (C.S.I.R.O.’s) patents on omega-3 production in terrestrial plants, which were successfully asserted and defended in Federal Court, including multiple related successful IPR and PGR proceedings.
• Australian Government’s (C.S.I.R.O.’s) patents on high amylose wheat (high resistant starch wheat), including related successful litigation in Federal Court, and successful Interference proceeding.
• Reexamination of Australian Government’s (C.S.I.R.O.’s)/Benetec patent relating to siRNA, and related successful Interference proceeding.
• Consolidated reexaminations of basic patent on NF-Kappa B owned by Harvard, MIT and the Whitehead Institute; patent successfully asserted at District Court level against Eli Lilly & Company and Amgen.
• Prosecution and Reexamination of Columbia University’s Axel patents on cotransformation and coamplification which were licensed by more than 30 companies who have paid Columbia more than $600 million in royalties and which were successfully litigated against Roche in Boston, Massachusetts and successfully defended against oppositions in Europe and Japan.
• Australian Government’s (C.S.I.R.O.’s) patents on ribozymes exclusively licensed to Johnson & Johnson.
• Savient Pharmaceuticals OXANDRIN® product for treating loss of body mass in HIV-1 infected patients.
• OSI Pharmaceutical’s U.S. and foreign patents for its TARCEVA® cancer drug which is approved for marketing in the United States, Europe and Japan, and is being comarketed with Genentech in the U.S. and by Roche outside the U.S.
• Teva Pharmaceutical’s U.S. and foreign patents for its RASAGILINE® drug for Parkinson’s disease which is approved for marketing in Europe and the United States.
• Teva Pharmaceutical’s U.S. and foreign patents for its COPAXONE® drug for Multiple Sclerosis which is approved for marketing in Europe and the United States.